Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2011 2
2012 1
2015 2
2016 2
2017 3
2018 3
2019 1
2020 5
2021 3
2022 3
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Engineering bispecific antibodies with defined chain pairing.
Krah S, Sellmann C, Rhiel L, Schröter C, Dickgiesser S, Beck J, Zielonka S, Toleikis L, Hock B, Kolmar H, Becker S. Krah S, et al. Among authors: toleikis l. N Biotechnol. 2017 Oct 25;39(Pt B):167-173. doi: 10.1016/j.nbt.2016.12.010. Epub 2017 Jan 27. N Biotechnol. 2017. PMID: 28137467 Review.
Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition.
Lipinski B, Unmuth L, Arras P, Becker S, Bauer C, Toleikis L, Krah S, Doerner A, Yanakieva D, Boje AS, Klausz K, Peipp M, Siegmund V, Evers A, Kolmar H, Pekar L, Zielonka S. Lipinski B, et al. Among authors: toleikis l. MAbs. 2023 Jan-Dec;15(1):2236265. doi: 10.1080/19420862.2023.2236265. MAbs. 2023. PMID: 37469014 Free PMC article.
Therapeutic antibodies and antibody fusion proteins.
Rohrbach P, Broders O, Toleikis L, Dübel S. Rohrbach P, et al. Among authors: toleikis l. Biotechnol Genet Eng Rev. 2003;20:137-63. doi: 10.1080/02648725.2003.10648041. Biotechnol Genet Eng Rev. 2003. PMID: 14997850 Review. No abstract available.
Discovery of potent allosteric antibodies inhibiting EGFR.
Fournier L, Pekar L, Leuthner B, Kolmar H, Toleikis L, Becker S. Fournier L, et al. Among authors: toleikis l. MAbs. 2024 Jan-Dec;16(1):2406548. doi: 10.1080/19420862.2024.2406548. Epub 2024 Sep 20. MAbs. 2024. PMID: 39304998 Free PMC article.
Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers.
Boje AS, Pekar L, Koep K, Lipinski B, Rabinovich B, Evers A, Gehlert CL, Krohn S, Xiao Y, Krah S, Zaynagetdinov R, Toleikis L, Poetzsch S, Peipp M, Zielonka S, Klausz K. Boje AS, et al. Among authors: toleikis l. MAbs. 2024 Jan-Dec;16(1):2315640. doi: 10.1080/19420862.2024.2315640. Epub 2024 Feb 19. MAbs. 2024. PMID: 38372053 Free PMC article.
Intein mediated high throughput screening for bispecific antibodies.
Hofmann T, Schmidt J, Ciesielski E, Becker S, Rysiok T, Schütte M, Toleikis L, Kolmar H, Doerner A. Hofmann T, et al. Among authors: toleikis l. MAbs. 2020 Jan-Dec;12(1):1731938. doi: 10.1080/19420862.2020.1731938. MAbs. 2020. PMID: 32151188 Free PMC article.
Bi-specific aptamers mediating tumor cell lysis.
Boltz A, Piater B, Toleikis L, Guenther R, Kolmar H, Hock B. Boltz A, et al. Among authors: toleikis l. J Biol Chem. 2011 Jun 17;286(24):21896-905. doi: 10.1074/jbc.M111.238261. Epub 2011 Apr 29. J Biol Chem. 2011. PMID: 21531729 Free PMC article.
32 results